ReviewBrain and behavior2026
Caffeine and Headache: Exploring the Multifaceted Relationship.
Review in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore the multifaceted relationship between caffeine and headache disorders, focusing on its dual role as both an analgesic and a potential trigger and to summarize the mechanisms underlying its anti-nociceptive effects.
methodThis narrative review synthesizes evidence from experimental, clinical, and epidemiological studies on caffeine's pharmacological actions, its role in adenosine receptor modulation, and its impact across different headache types, including migraine, hypnic headache, post-dural puncture headache (PDPH), medication-overuse headache (MOH), and caffeine-withdrawal headache.
findingsCaffeine exerts analgesic effects through adenosine receptor antagonism, prostaglandin inhibition, GABA-A modulation, and cholinergic facilitation while also enhancing the efficacy of analgesics such as nonsteroidal anti-inflammatory medications (NSAIDs), acetaminophen, and opioids. In migraine, it demonstrates a dual role, relieving attacks by counteracting adenosine-mediated vasodilation and improving drug absorption yet potentially triggering them when intake is excessive or inconsistent due to mechanisms such as magnesium depletion, diuresis, and sleep disruption. Beyond migraine, caffeine shows therapeutic benefit in hypnic headache and PDPH, but chronic use may contribute to MOH through neuroadaptive changes. Abrupt cessation of caffeine often provokes caffeine-withdrawal headache.
conclusionCaffeine plays a complex role in headache disorders, acting as both a therapeutic agent and a potential trigger. Its effects depend on dosage, timing, individual susceptibility, and headache subtype. Understanding these mechanisms is essential for guiding clinical recommendations and optimizing caffeine use in headache management.Caffeine plays a complex role in headache disorders, acting as both a therapeutic agent and a potential trigger. In migraine, it demonstrates a dual role, either relieving or triggering. Beyond migraine, caffeine shows therapeutic benefit in hypnic headache, spontaneous intracranial hypotension, and PDPH, but chronic use may exacerbate idiopathic intracranial hypertension and contribute to MOH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.